1.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

2.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

3.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

4.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

5.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

6.

POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

1.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

2.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

3.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

4.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

5.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

6.

THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY

1.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

2.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

3.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

4.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

5.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

6.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

7.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

8.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

9.

THU0712 Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis

1.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

2.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

3.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

4.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

5.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

6.

Improvements in Productivity at Paid Work and Within the Household, and Increased Participation in Daily Activities Over 52 Weeks of Certolizumab Pegol Treatment of Rheumatoid Arth...

1.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

2.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

3.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

4.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

5.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

6.

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

1.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

2.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

3.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

4.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

5.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

6.

AB0462 Up to 5-year retention of abatacept in belgian patients with moderate-to-severe ra: prospective data from the real-world action study

1.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

2.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

3.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

4.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

5.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

6.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

7.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

8.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

9.

Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria

1.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

2.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

3.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

4.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

5.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

6.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

7.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

8.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

9.

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective s...

1.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

2.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

3.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

4.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

5.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

6.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

7.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

8.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

9.

Calibration and validation of the Dutch-Flemish PROMIS pain interference item bank in patients with chronic pain

1.

Calibration of the Dutch-Flemish PROMIS Pain Behavior item bank in patients with chronic pain